Xinchen Pharmaceutical

Jiangsu Hengrui Pharmaceutical Co., Ltd. was founded in 1970 and listed on the Shanghai Stock Exchange in 2000 with stock code 600276. It is a major research and production base for surgical medications and anti-tumor drugs in China, the leading large-scale pharmaceutical enterprise with strong innovation capability in the country, currently with a market value exceeding 200 billion yuan, and is a national incubator base for the "Major New Drug Creation" program.

Jiangsu Xinchen Pharmaceutical Co., Ltd. is the wholly-owned marketing company of Jiangsu Hengrui Pharmaceutical Co., Ltd., which is one of the first national "Top 100 Innovation Pilot Enterprises". It is responsible for the market promotion of the group's products in anesthesia, analgesia, muscle relaxation, sedation, respiration, antibiotics, nervous system, gastrointestinal nutrition, and other series. Multiple products such as Kateli, Aisikang, Aibeining, Datuomei, Kajn, and Pating are sold simultaneously in Europe and America. It covers multiple clinical fields including anesthesiology, ICU, pain management, neurology, dermatology, breast surgery, respiratory medicine, and others. It is one of the main suppliers of surgical medication series products in China. The company has established over 300 offices nationwide, currently employs nearly 5,000 people, and has sales of nearly 5 billion yuan.